Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod versus standard disease-modifying therapy switch study in relapsing-remitting multiple sclerosis
2010-024017-31Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: Change in treatment satisfaction at 6 months. Started Feb 2011; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-024017-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024017-31.